Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1866-1871

  Seyedmousavi, Seyedmojtaba ^a   Melchers, Willem J G ^a   Mouton, Johan W ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; PYRROLE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FUNGAL STRAIN; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; INVASIVE ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL; TANDEM REPEAT; TREATMENT DURATION;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGAL PROTEINS; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 84875134112     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02226-12     Document Type: Article

References (50)

1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
2. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
3. Verweij PE, Howard SJ, Melchers WJ, Denning DW. 2009. Azoleresistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
4. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219. doi:10.1371/journal.pmed.0050219.
5. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, Kuijper EJ, Van Tiel FH, Melchers WJ, Verweij PE. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg. Infect. Dis. 17:1846 -1854.
6. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. 2011. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55:4465-4468.
7. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. 2011. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67:362-366.
8. Tashiro M, Izumikawa K, Minematsu A, Hirano K, Iwanaga N, Ide S, Mihara T, Hosogaya N, Takazono T, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, Miyazaki T, Nishino T, Tsukamoto M, Kakeya H, Yamamoto Y, Yanagihara K, Yasuoka A, Tashiro T, Kohno S. 2012. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates in Nagasaki, Japan. Antimicrob. Agents Chemother. 56:584 -587.
9. Verweij PE, Mellado E, Melchers WJ. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.
10. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW. 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28:450-453.
11. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865.
12. Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW. 2011. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J. Infect. Dis. 203:1324 -1332.
13. Seyedmousavi S, Bruggemann RJM, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW. 2013. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J. Antimicrob. Chemother. 68:385-393.
14. Seyedmousavi S, Meletiadis J, Melchers WJG, Rijs AJMM, Verweij PE, Mouton JW. 2013. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus Antimicrob. Agents Chemother. 57:796-803.
15. Seyedmousavi S, Brüggemann RJM, Melchers WJG, Verweij P, Mouton JW. 2013. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 57:303-308.
16. Hiemenz JW, Walsh TJ. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl 2):S133-S144.
17. Leenders AC, de Marie S. 1996. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 10:1570 -1575.
18. Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, Proffitt RT. 2006. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob. Agents Chemother. 50:2122-2131.
19. Takemoto K, Yamamoto Y, Ueda Y, Kanazawa K, Yoshida K, Niki Y. 2009. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model. Chemotherapy 55:105-113.
20. Mouton JW, te Dorsthorst DT, Meis JF, Verweij PE. 2009. Doseresponse relationships of three amphotericin B formulations in a nonneutropenic murine model of invasive aspergillosis. Med. Mycol. 47:802-807.
21. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. 2007. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 51:1253-1258.
22. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833.
23. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46: 1813-1821.
24. Rodriguez-Tudela JL, Arendrup MC, Arikan S, Barchiesi F, Bille J, Cuenca-Estrella E CEMM, Dannaoui EE, Denning DW, Donnelly JP, Fegeler W, Lass-Flörl C, Moore C, Richardson M, Gaustad P, Schmalreck A, Velegraki AA, Verweij P. 2008. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
25. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. 2010. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54:4758-4764.
26. Seyedmousavi S, Melchers WJ, Verweij PE, Mouton JW. 2011. Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. Curr. Opin. Pharmacol. 11:486-493.
27. Andes D, Stamsted T, Conklin R. 2001. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob. Agents Chemother. 45:922-926.
28. Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. 2006. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50:469-473.
29. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ. 2000. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182:274 -282.
30. Turnidge JD, Gudmundsson S, Vogelman B, Craig WA. 1994. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J. Antimicrob. Chemother. 34:83-92.
31. Warn PA, Morrissey J, Moore CB, Denning DW. 2000. In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob. Agents Chemother. 44:2664 -2671.
32. Denning DW, Warn P. 1999. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob. Agents Chemother. 43:2592-2599.
33. Andes D, Safdar N, Marchillo K, Conklin R. 2006. Pharmacokineticpharmacodynamic comparison of amphotericin B (AMB) and two lipidassociatedAMBpreparations, liposomalAMBandAMBlipid complex, in murine candidiasis models. Antimicrob. Agents Chemother. 50:674-684.
34. Ernst EJ, Yodoi K, Roling EE, Klepser ME. 2002. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob. Agents Chemother. 46:578 -581.
35. Ernst EJ, Klepser ME, Pfaller MA. 2000. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44: 1108-1111.
36. Leenders AC, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA. 1996. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. J. Antimicrob. Chemother. 38:215-225.
37. Olson JA, Adler-Moore JP, Jensen GM, Schwartz J, Dignani MC, Proffitt RT. 2008. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob. Agents Chemother. 52:259 -268.
38. Clemons KV, Stevens DA. 2004. Comparative efficacies of four amphotericin B formulations - Fungizone, amphotec (Amphocil), AmBisome, and Abelcet - against systemic murine aspergillosis. Antimicrob. Agents Chemother. 48:1047-1050.
39. Clemons KV, Espiritu M, Parmar R, Stevens DA. 2005. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875.
40. Olson JA, George A, Constable D, Smith P, Proffitt RT, Adler-Moore JP. 2010. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob. Agents Chemother. 54:3884 -3894.
41. Lepak AJ, Andes DR. 2011. Antifungal PK/PD considerations in fungal pulmonary infections. Semin. Respir. Crit. Care Med. 32:783-794.
42. Hong Y, Shaw PJ, Nath CE, Yadav SP, Stephen KR, Earl JW, McLachlan AJ. 2006. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob. Agents Chemother. 50:935-942.
43. Lewis RE. 2011. Current concepts in antifungal pharmacology. Mayo Clinic Proc. 86:805-817.
44. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R, AmBiLoad Trial Study Group. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (Am-BiLoad trial). Clin. Infect. Dis. 44:1289 -1297.
45. Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, Schmatz DM, Liberator PA, Douglas CM. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474 -3481.
46. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. 2013. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 57:579 -585.
47. Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E. 2007. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses 50:196 -200.
48. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, McGee ZA, Cate TR, Cobbs CG, Warner JF, Alling DW. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301:126 -131.
49. te Dorsthorst DT, Verweij PE, Meis JF, Mouton JW. 2005. Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 49: 4220-4226.
50. Te Dorsthorst DT, Mouton JW, van den Beukel CJ, van der Lee HA, Meis JF, Verweij PE. 2004. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates. Antimicrob. Agents Chemother. 48:3147-3150.